Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
19 January 2018
Melanoma Institute Australia is delighted to be the charity partner for the Toyota Country Music Festival 2018 in Tamworth, with the traditional festival hat giveaway to raise vital funds for research into melanoma prevention and treatment.
Melanoma is the most deadly form of skin cancer. Australia has one of the highest rates in the world with one person dying from the disease every five hours. It is the most common cancer affecting 15 to 39 year olds and incidence in the over 60s age bracket is also increasing. 14,000 Australians are expected to be diagnosed with melanoma this year.
Melanoma Institute Australia is leading the world charge to prevent melanoma and find a cure, and funds raised at this year’s Toyota Country Music Festival through their annual hat fundraiser will help fuel ongoing research.
Toyota ambassadors, including Lee himself and The McClymonts, will be making surprise appearances to support this cause as well during the Festival to meet fans and show their support in raising awareness of sun safety.
Prevention is the key to saving lives from melanoma. All Australians are urged to wear SPF 50+ sunscreen and re-apply at least every two hours or after swimming or activity; cover up with a broad-brimmed hat, long pants and shirt and sunglasses; and seek shade in the heat of the day.
Hats will be available daily at the Toyota Fanzone at 10am, 12pm, 2pm and 4pm in exchange for a two-dollar donation with all proceeds going to Melanoma Institute Australia
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.